Determining The Side Effects Of Covid-19 (Sinovac) Vaccination On Nurses; An Independent Descriptive Study

Abstract

Objective: It is important to protect nurses fighting against the COVID-19 pandemic through vaccination. This study aims to determine the incidence rate of side effects experienced by nurses after their COVID-19 (Sinovac) vaccination and relevant factors. Methods: This is a descriptive design study. The sample of the study included 355 nurses who received the Sinovac COVID-19 vaccine in Turkey and who agreed to participate in the study. Data were collected using a questionnaire which was written by the researchers and gathered information on the nurses’ sociodemographic and professional characteristics, health status, habits, and vaccine complications. Results: The study included 355 nurses, of which 82.3% were female. Their median age was 35.42±9.67, and their mean BMI was 24.87±4.54. The most common local side effect experienced after the vaccination was pain (54.6%) while the most common systemic effects were fatigue (39.2%) and headache (34.1%). Pain, among local side effects, was significantly higher among male nurses (p= 0.001) and those who worked more than 40 hours a week (p= 0.001). The systemic side effect of fatigue was experienced at a higher rate among nurses who were diagnosed with COVID-19 before their vaccination (p=0.004), those who drank alcohol (p= .028), and those who worked more than 40 hours a week (p=0.012). The systemic side effect of fever was more common among nurses with chronic conditions (p= .037). Conclusions: The most common systemic side effect experienced after the COVID-19 vaccination was reported as fatigue and the most common local side effect was pain. Considering the relevant factors that affected the incidence rates of side effects, it would be suitable to plan the weekly working hours of nurses no longer than 40 hours. It can be recommended to conduct more randomized controlled studies to determine what else weekly working hours affect among nurses.

Keywords

• nurse
• side effect
• vaccine
• covid-19

Hemşirelerde Covid-19 Aşısı (Sinovac) Sonrası Görülen Yan Etkilerin Belirlenmesi; Bağımsız Tanımlayıcı Çalışma

Abstract

Amaç: COVİD 19 pandemisi ile mücadelede hemşirelerin aşı yoluyla bağışıklanarak korunmaları önem arz etmektedir. Çalışmanın amacı, COVİD 19 aşısı (Sinovac) sonrası hemşirelerde yan etki görülme oranları ve ilişkili faktörlerin belirlenmesidir. Yöntem: Araştırma tanımlayıcı tipte tasarıma sahiptir. Araştırmanın örneklemini Türkiye’de COVİD-19 aşısı yaptıran ve gönüllü olarak çalışmaya katılmayı kabul eden 355 hemşire oluşturmuştur. Veriler, araştırmacılar tarafından oluşturulan ve hemşirelerin sosyo-demografik ve mesleki özellikleri, sağlık durumları, alışkanlıkları ve aşı komplikasyonlarına ilişkin bilgilerini sorgulayan anket formu ile çevirim içi olarak toplanmıştır. Bulgular: Çalışmaya 355 hemşire katılmıştır. Hemşirelerin %82,3’ü kadındır. Ortanca yaşları 35,42±9,67, BKİ ortalamaları 24,87±4,54’dır. Aşılama sonrası en sık görülen lokal yan etki ağrı (%54,6) ve en sık görülen sistemik etkiler ise yorgunluk (%39,2) ve baş ağrısı (%34,1) olarak bulunmuştur. Lokal yan etkilerden ağrı erkek cinsiyette (p= 0,001) ve haftalık olarak 40 saatin üzerinde çalışan (p= 0,001) hemşirelerde istatiksel olarak anlamlı düzeyde daha yüksek bulunmuştur. Aşılanma öncesi COVİD-19 tanısı alanlarda (p=0,004), alkol kullananlarda (p= 0,028) ve haftalık 40 saatin üzerinde çalışanlarda (p= 0,012), yorgunluk sistemik yan etkisi daha yüksek oranda görülmüştür. Ateş sistemik yan etkisi ise, kronik hastalığı olan hemşirelerde daha çok görülmüştür (p= 0037). Sonuç: COVİD 19 aşılaması sonrası en sık görülen sistemik yan etki yorgunluk ve lokal yan etki ise ağrı olarak bildirilmiştir. Yan etkilerin görülme oranlarını etkileyen ilişkili faktörlere bakıldığında hemşirelerin haftalık çalışma saatlerinin 40 saatten fazla olmayacak şekilde planlanması uygun olacaktır. Haftalık çalışma saatlerinin hemşirelerde başka neleri etkiliyor olduğuna dair randomize kontrollü çalışmaların yapılması önerilebilir.

Keywords

• Hemşire
• COVİD-19
• Aşı
• Yan etki

References

1. 1. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5).10.1183/13993003.01112-2020
2. 2. WHO. WHO Coronavirus (COVID-19) Dashboard. 2021.https://covid19.who.int/. Erişim tarihi: 26.04.2021
3. 3. SağlıkBakanlığı. Covid-19 Aşısı Bilgilendirme Portalı. 2020.https://covid19asi.saglik.gov.tr/TR-77823/a.html. Erişim tarihi: 28.06.2021
4. 4. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020;52(4):583-9.10.1016/j.immuni.2020.03.007
5. 5. WHO. Global research on coronavirus disease (COVID-19). Erişim tarihi: 28042020. 2020.Erişim adresi: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov
6. 6. Kim JH, Hotez P, Batista C, Ergonul O, Figueroa JP, Gilbert S, et al. Operation Warp Speed: implications for global vaccine security. The Lancet Global Health. 2021;9(7):e1017-e21.10.1016/s2214-109x(21)00140-6
7. 7. Kwok KO, Li KK, Wei WI, Tang A, Wong SYS, Lee SS. Editor's Choice: Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. Int J Nurs Stud. 2021;114:103854.10.1016/j.ijnurstu.2020.103854
8. 8. Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021;10(7):1-18.10.3390/jcm10071428

9. 9. Riad A, Sağıroğlu D, Üstün B, Attia S, Klugar M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study Among Healthcare Workers in Turkey. SSRN Electronic Journal. 2021.10.2139/ssrn.3820571
10. 10. Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845-54.10.1016/s0140-6736(20)31208-3
11. 11. Zhang X, Jiang Z, Yuan X, Wang Y, Huang D, Hu R, et al. Nurses reports of actual work hours and preferred work hours per shift among frontline nurses during coronavirus disease 2019 (COVID-19) epidemic: A cross-sectional survey. Int J Nurs Stud Adv. 2021;3:100026.10.1016/j.ijnsa.2021.100026
12. 12. Grech V, Gauci C, Agius S. Vaccine hesitancy among Maltese healthcare workers toward influenza and novel COVID-19 vaccination. Early Hum Dev. 2020:105213.10.1016/j.earlhumdev.2020.105213
13. 13. Cerise F, Moran B, Bhavan K. Delivering Covid-19 Vaccines by Building Community Trust. NEJM. 2021;January(8):1-9.10.1056/CAT.20.0692
14. 14. SağlıkBakanlığı. Sağlık İstatistikleri Yıllığı 2019 Haber Bülteni. 2019.https://dosyamerkez.saglik.gov.tr/Eklenti/39024,haber-bulteni-2019pdf.pdf?0. Erişim tarihi: 05.03.2021
15. 15. TCSağlıkBakanlığı. TC Sağlık Bakanlığı Covid-19 Bilgilendirme Platformu. 2021.https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html. Erişim tarihi: 27.04.2021
16. 16. Yıldırım Kaptanoğlu A. Sağlık Alanında Hipotezden Teze. Beşir Kitabevi İstanbul. 2013,
17. 17. Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020:1-4.10.1007/s40475-020-00201-6
18. 18. Çetintepe SP, İlhan MN. COVİD-19 Salgınında Sağlık Çalışanlarında Risk Azaltılması. Journal of Biotechnology and Strategic Health Research. 2020;1(Özel sayı):50-4.10.34084/bshr.712539
19. 19. Karaçam Z. STROBE Gözlemsel Araştırmalarda Yazım Standardizasyonu. Ankara Nobel Tıp Kitabevi. 2018;Ankara,
20. 20. SB. T.C. Sağlik Bakanliği Covid-19 Aşisi Bİlgİlendİrme Platformu. 2021.https://covid19asi.saglik.gov.tr/. Erişim tarihi: 10.06.2021
21. 21. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-54.10.1016/S0140-6736(20)31208-3
22. 22. Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021:1-8.10.1080/14760584.2021.1925112
23. 23. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021.10.1016/S1473-3099(21)00224-3
24. 24. Song JY, Cheong HJ, Kim SR, Lee SE, Kim SH, Noh JY, et al. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers. J Korean Med Sci. 2021;36(15):e110.10.3346/jkms.2021.36.e110
25. 25. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6).10.3390/vaccines9060577
26. 26. Halim M, Halim A, Tjhin Y. COVID-19 Vaccination Efficacy and Safety Literature Review. Journal of Immunology and Allergy. 2021;3(1):1-10.10.37191/Mapsci-2582-4333-3(1)-058
27. 27. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021:1-13.10.1007/s12291-021-00968-z
28. 28. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021;21(6):803-12.10.1016/s1473-3099(20)30987-7
29. 29. Lee J, Lee HJ, Hong Y, Shin YW, Chung S, Park J. Risk Perception, Unhealthy Behavior, and Anxiety Due to Viral Epidemic Among Healthcare Workers: The Relationships With Depressive and Insomnia Symptoms During COVID-19. Front Psychiatry. 2021;12:615387.10.3389/fpsyt.2021.615387
30. 30. Sharma T. Work Life Balance in COVID Time. J Perioper Crit Intensive Care Nurs. 2020;1(151):1-3.10.35248/2471-9870.20.S1.151
31. 31. Felix Claret E, Umamaheswari R, Venkateswaran P. Linkage between the Overall Work Life and Life Satisfaction of Nurses at Hospitals in Coimbatore District at COVID – 19. Indian Journal of Natural Sciences 2020;10(61):27493-501.www.tnsroindia.org.in ©IJONS
32. 32. Heath C, Sommerfield A, von Ungern-Sternberg BS. Resilience strategies to manage psychological distress among healthcare workers during the COVID-19 pandemic: a narrative review. Anaesthesia. 2020;75(10):1364-71.10.1111/anae.15180
33. 33. Üzar Özçetin YS, Sarıoğlu G, Dursun Sİ. Onkoloji Hemşirelerinin Psikolojik Sağlamlık, Tükenmişlik ve Psikolojik İyi Oluş Düzeyler. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. 2019;11(Suppl.1):147-64.10.18863/pgy.598097
34. 34. TÜBA. COVID-19 Pandemi Değerlendirme Raporu. Türkiye Bilimler Akademisi 2020;Nisan:165-85.http://www.tuba.gov.tr/tr/yayinlar/suresiz-yayinlar/raporlar/bagisiklik-beslenme-ve-yasam-tarzi-raporu. Erişim tarihi: 19.06.2021
35. 35. Akkaya A, Karadağ M. Ameliyathane Hemşirelerinin Çalışma Ortamından Kaynaklanan Mesleki Risklerinin ve Sağlık Sorunlarının Belirlenmesi. EGEHFD 2021;3(1):1-11.https://dergipark.org.tr/en/download/article-file/1290540
36. 36. Xie W, Li R, He M, Cui F, Sun T, Xiong J, et al. Prevalence and risk factors associated with headache amongst medical staff in South China. J Headache Pain. 2020;21(1):5.10.1186/s10194-020-1075-z
37. 37. Arslan M, Aydemir İ. Relationship between emotional appetite, eating attitudes, sleep quality, and body mass index in healthcare workers: a multi-centre study. Psychiatry and Clinical Psychopharmacology. 2019;29(3):346-53.10.1080/24750573.2019.1627694
38. 38. Cummings JR, Ackerman JM, Wolfson JA, Gearhardt AN. COVID-19 stress and eating and drinking behaviors in the United States during the early stages of the pandemic. Appetite. 2021;162:105163.10.1016/j.appet.2021.105163
39. 39. Galali Y. The impact of COVID-19 confinement on the eating habits and lifestyle changes: A cross sectional study. Food Sci Nutr. 2021;9(4):2105-13.10.1002/fsn3.2179
40. 40. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021;21(2):181-92.10.1016/s1473-3099(20)30843-4
41. 41. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77 e3.10.1016/j.cmet.2020.04.021
42. 42. Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission. Br J Anaesth. 2020;125(2):e254-e5.10.1016/j.bja.2020.04.056
43. 43. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-51.10.3760/cma.j.issn.0254-6450.2020.02.003
44. 44. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020;92(10):1915-21.10.1002/jmv.25889